Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-034001	Application No. 09/805,840
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Mundy *et al.*	
(37 CFR 1.98(b))		Filing Date March 13, 2001	Group Art Unit 1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
MH	AA	5,840,299	11/1998	Bendig			
MH	AB	6,632,927	10/2003	Adair et al.			
MH	AC	5,885,786	03/1999	Cabot, Myles			
MH	AD	6,692,742	2/17/2004	Nakamura			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
MH	AE	WO 97/49428	12/31/1997	WIPO			X (abst only)	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
MH	AF	Amit et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution," Science, 233(4765):747-753 (1986)
	AG	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA, 79(6):1979-83 (Mar 1982)
	AH	Alexanian R. et al., "Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens." JAMA, 208(9):1680-5 (Jun 2 , 1969)
	AI	Owens, R.J., Young, R.J., "The genetic engineering of monoclonal antibodies," J. Immunol. Methods, 168(2):149-165 (1994)
	AJ	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," Blood, 87:1495-1501 (1996).
	AK	Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," N. Engl. J. Med, 335:91-97 (1996)
	AL	Atkins C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N. Engl. J. Med., 335:1844 (1996)
	AM	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N. Engl. J. Med., 335:1844-1845 (1996)
	AN	Attal et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma – In Reply," N. Engl. J. Med., 335:1844-1845 (1996)
	AO	Bataille, R. et al., "Serum levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J. Clin. Invest., 84:2008-2011 (1989).
	AP	Bataille, R. et al., "Mechanisms of Bone Lesions in Multiple Myeloma," Hematology/Oncology Clinics of North America, 6:285-295 (1992).
MH	AQ	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," Blood, 86:685-691 (1995)

Examiner Signature	Date Considered
Maher Haddad	5/12/06

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-034001	Application No. 09/805,840
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Mundy *et al.*	
(37 CFR 1.98(b))		Filing Date March 13, 2001	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
MH	AR	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," J. Clin. Oncol., 16:2572 (1998)
	AS	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma – In Reply," J. Clin. Oncol., 16:2572-2573 (1998)
	AT	Boyce, B.F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," Endocrinology, 125:2780-2783 (1989).
	AU	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," Stem Cells, 13 (suppl. 2):35-39 (1995)
	AV	Epstein J., "Myeloma Phenotype: Clues to Disease Origin and Manifestation," Hematology/Oncology Clinics of North America, 6:249-256 (1992).
	AW	Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," Bone, 20:515-520 (1997).
	AX	Gosslar, U. et al., "Predominant Role of α4-integrins for distinct steps of lymphoma metastasis," Proc. Natl. Acad. Sci. USA, 93:4821-4826 (1996)
	AY	MacDonald, B. R. et al., ""Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," J. Bone and Mineral Research, 1:227-233 (1986).
	AZ	Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin α4β1 into Tumor Cells," AM J. Pathol., 148:55-61 (1996).
	AAA	Mundy, G. R., "Myeloma Bone Disease," Euro J. Cancer, 34:246-251 (1998).
	ABB	Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding to Bone Marrow Stromal Cells Via An α4β1-VCAM-1 Interaction," Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); Bone, 23(5 Supplement):p. S180 (1998)
	ACC	Papayannapoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates treated with anti-VLA_4 integrin," Proc. Natl. Acad. Sci. USA 90:9374-9378 (1993).
	ADD	Qian, F. et al., "Expression of the Integrin α4β1 on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," Cell, 77:335-347 (1994).
	AEE	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," Brit. J. Cancer, 76:451-460 (1997).
	AFF	Roodman, G. D., "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Database Medline 'Online!: US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession no. 1998026745, abstract.
	AGG	Akatsu et al., "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation in Vitro," Database BIOSIS 'Online!: Biosciences Information Service, Philadelphia, PA, US (August 1998) Database accession no. PREV199800429141, abstract.
	AHH	Michigami et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4Beta1 Integrin – VCAM-1 is required for the Development of Osteolysis," Database SCISEARCH 'Online!, retrieved from STN, Database accession no. 684996.
MH	AII	Mori et al., "Anti-α4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions," Journal of Bone and Mineral Research, 14 Supp. 1, p. S173, Abstract 1161 (1999). 1999

Examiner Signature	Date Considered
Maher Haddad	5/12/06

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.